Menu Search
Equities

Fagron NV

4A5:DUS

Fagron NV

Actions
  • Price (EUR)18.90
  • Today's Change-0.04 / -0.21%
  • Shares traded--
  • 1 Year change+12.63%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 07:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Fagron NV, formerly Arseus NV, is a Belgium-based company that is active in the healthcare sector. The Company specializes in the development, marketing and distribution of healthcare products and services intended for healthcare professionals and institutions. It operates through the following segments: Essentials, enable pharmacists to compound safe products and optimize their compounding process with equipment and packaging. The portfolio includes pharmaceutical raw materials, compounding equipment, packaging, and supplies; Brands, focuses on developing semi-finished products and pharmaceutical-grade vehicles and reduce the workload for pharmacists; Compounding Services, utilizes raw materials from the Essentials segment and vehicles from the Brands segment for compounding activities, offering both sterile and non-sterile compounded products tailored to patients' specific needs.

  • Revenue in EUR (TTM)820.76m
  • Net income in EUR77.94m
  • Incorporated2007
  • Employees3.46k
  • Location
    Fagron NVVenecoweg 20ANAZARETH 9810BelgiumBEL
  • Phone+32 80012880
  • Fax+32 92162491
  • Websitehttps://fagron.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.